Management of Stage III Oral Cavity Squamous Cell Carcinoma in Light of the New Staging System: a Critical Review

Imagem de Miniatura
Arquivos
art_MATOS_Management_of_Stage_III_Oral_Cavity_Squamous_Cell_2023.PDF (729.76 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
Citação
CURRENT ONCOLOGY REPORTS, v.25, n.2, p.107-113, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose of Review Oral squamous cell carcinoma (OSCC) patients have a poor prognosis, especially in advanced stages. AJCC/UICC staging system 8th edition (TNM8) included depth of invasion (DOI) as part of T staging and stage III has become a heterogeneous group of lesions, composed of patients with larger DOI and/or width. Additionally, stage III includes N1, regardless of the primary tumor width or DOI. The real prognostic value of each of these characteristics and the need for adjuvant treatment for stage III patients is not well established. Recent Findings TNM8 stratified OSCC into prognostic groups based on overall survival. Extranodal extension, positive or close margins, pT3 or pT4 tumors, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion are the main adverse features for OSCC, and adjuvant treatment is largely recommended for these patients. Summary Stage III patients should be addressed with caution. So far, there is no significant evidence for recommending or excluding adjuvant treatment for stage III OSCC without adverse features. The authors largely recommend adjuvant radiotherapy for these cases, especially because pT3 without adverse features is rare. Further studies on this topic are necessary.
Palavras-chave
Oral neoplasms, Neoplasm staging, Lymph node metastasis, Prognosis
URI
https://observatorio.fm.usp.br/handle/OPI/51371
Referências
  1. Aires FT, 2017, ORL J OTO-RHINO-LARY, V79, P347, DOI 10.1159/000485627
  2. Almangush A, 2020, HEAD NECK-J SCI SPEC, V42, P3002, DOI 10.1002/hed.26344
  3. Amin M.B., 2017, AJCC CANC STAGING MA, V8th ed.
  4. Bernier J, 2004, NEW ENGL J MED, V350, P1945, DOI 10.1056/NEJMoa032641
  5. Best CAE, 2019, J OTOLARYNGOL-HEAD N, V48, DOI 10.1186/s40463-019-0396-x
  6. Bobdey S, 2018, ORAL ONCOL, V81, P10, DOI 10.1016/j.oraloncology.2018.04.002
  7. Bobdey S, 2016, HEAD NECK-J SCI SPEC, V38, P1826, DOI 10.1002/hed.24507
  8. Caldeira PC, 2020, ORAL DIS, V26, P1357, DOI 10.1111/odi.13194
  9. Chang BY, 2018, J CANCER, V9, P2107, DOI 10.7150/jca.24530
  10. Chen WC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003770
  11. Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646
  12. d'Alessandro AF, 2015, BRAZ J OTORHINOLAR, V81, P248, DOI 10.1016/j.bjorl.2015.03.004
  13. Ferreli F, 2021, ORAL ONCOL, V122, DOI 10.1016/j.oraloncology.2021.105540
  14. Gokavarapu S, 2015, OR SURG OR MED OR PA, V120, DOI 10.1016/j.oooo.2015.08.002
  15. Hamman J, 2022, LARYNGOSCOPE, V132, P307, DOI 10.1002/lary.29690
  16. Hasmat S, 2019, HEAD NECK-J SCI SPEC, V41, P3992, DOI 10.1002/hed.25940
  17. Huang SH, 2020, ORAL ONCOL, V102, DOI 10.1016/j.oraloncology.2019.104563
  18. Huang SJ, 2021, OR SURG OR MED OR PA, V131, P319, DOI 10.1016/j.oooo.2020.10.026
  19. Huang TH, 2019, ORAL ONCOL, V89, P133, DOI 10.1016/j.oraloncology.2018.12.032
  20. Lee Oh Hyeong, 2022, J Oral Maxillofac Surg, V80, P553, DOI 10.1016/j.joms.2021.11.003
  21. Leite AKN, 2014, ACTA OTORHINOLARYNGO, V34, P389
  22. Li Y, 2017, CANCER MED-US, V6, P1002, DOI 10.1002/cam4.1021
  23. Mair M, 2018, HEAD NECK-J SCI SPEC, V40, P1667, DOI 10.1002/hed.25161
  24. Matos LL, 2017, ORAL ONCOL, V71, P47, DOI 10.1016/j.oraloncology.2017.05.020
  25. Matsuura D, 2018, LARYNGOSCOPE, V128, P1113, DOI 10.1002/lary.26935
  26. Membreno PV, 2021, HEAD NECK-J SCI SPEC, V43, P3165, DOI 10.1002/hed.26779
  27. Mermod M, 2016, ORAL ONCOL, V62, P60, DOI 10.1016/j.oraloncology.2016.10.003
  28. Mishra RC, 1996, EUR J SURG ONCOL, V22, P502, DOI 10.1016/S0748-7983(96)92969-8
  29. Montero PH, 2015, SURG ONCOL CLIN N AM, V24, P491, DOI 10.1016/j.soc.2015.03.006
  30. Montero PH, 2014, CANCER-AM CANCER SOC, V120, P214, DOI 10.1002/cncr.28407
  31. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), 2022, HEAD NECK CANC
  32. Nie ZL, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08106-x
  33. PETERS LJ, 1993, INT J RADIAT ONCOL, V26, P3, DOI 10.1016/0360-3016(93)90167-T
  34. Pinto FR, 2014, EUR ARCH OTO-RHINO-L, V271, P1747, DOI 10.1007/s00405-013-2704-9
  35. Pinto FR, 2011, REV ASSOC MED BRAS, V57, P171, DOI 10.1590/S0104-42302011000200014
  36. Russo D, 2021, CANCERS, V13, DOI 10.3390/cancers13225755
  37. Salama JK, 2011, ORAL ONCOL, V47, P554, DOI 10.1016/j.oraloncology.2011.05.002
  38. Shabtay NW, 2020, OR SURG OR MED OR PA, V130, P363, DOI 10.1016/j.oooo.2020.04.810
  39. Shim Su Jung, 2010, Radiat Oncol, V5, P43, DOI 10.1186/1748-717X-5-43
  40. Shrime MG, 2010, ARCH OTOLARYNGOL, V136, P225, DOI 10.1001/archoto.2010.22
  41. Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21590, 10.3322/caac.21708]
  42. Sridharan S, 2019, CANCER-AM CANCER SOC, V125, P3198, DOI 10.1002/cncr.32199
  43. Sun W, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016206
  44. Tandon S, 2022, LARYNGOSCOPE, V132, P1594, DOI 10.1002/lary.29990
  45. Torrecillas V, 2018, ORAL ONCOL, V85, P1, DOI 10.1016/j.oraloncology.2018.07.019
  46. Tsai TY, 2022, LARYNGOSCOPE, V132, P88, DOI 10.1002/lary.29674
  47. Tu IWH, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.836803
  48. Warshavsky A, 2019, JAMA OTOLARYNGOL, V145, P542, DOI 10.1001/jamaoto.2019.0784
  49. Zhou JY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.652553
  50. Zhu J, 2019, ACTA OTO-LARYNGOL, V139, P1038, DOI 10.1080/00016489.2019.1655167

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/28
Artigos e Materiais de Revistas Científicas - ODS/03